The role of brevican in glioma: promoting tumor cell motility in vitro and in vivo

BMC Cancer

Renquan Lu⁵  Chengsheng Wu¹  Lin Guo⁵  Yingchao Liu³  Wei Mo¹  Huijie Wang²  Jianbo Ding⁴  Eric T Wong⁶  Min Yu¹ 

[1] Department of Biochemistry and Molecular Biology and the Key Laboratory of Molecular Medicine, Ministry of Education, Shanghai 200032, China

[2] Department of Clinical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

[3] Department of Neurosurgery, Provincial hospital affiliated to Shandong University, Jinan, China

[4] Gamma Knife Center, Huashan Hospital, Shanghai, China

[5] Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China

[6] Brain Tumor Center and Neuro-Oncology Unit, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

关键词: Tumorigenicity;    Motility;    Astrocytoma;    Glioma;    Brevican;   

Others  :  1080007
DOI  :  10.1186/1471-2407-12-607

 received in 2012-10-09, accepted in 2012-12-11,  发布年份 2012

【 摘 要 】

Background

Malignant glioma is a common primary tumor of the central nervous system. Brevican, an abundant extracellular matrix component in the adult brain, plays a critical role in the process of glioma. The mechanisms for the highly invasive behavior of gliomas are still poorly understood. The aim of this study was to examine whether brevican is a predictor of glioma and its roles in glioma cell motility.

Methods

In this study, immunohistochemistry staining for brevican expression was performed in malignant gliomas and benign controls. We also explored the effects of brevican on cell adhesion and migration in brevican-overexpressed cells. Knockdown of brevican expression was achieved by stable transfection of U251 cells transduced with a construct encoding a short hairpin DNA directed against the brevican gene, which correspondingly, down-regulated the proliferation, invasion and spread of brevican-expressing cells. Moreover, the role of brevican in the growth and progression of glioma was demonstrated by in vivo studies.

Results

Our results provide evidence for the molecular and cellular mechanisms that may underlie the motility-promoting role of brevican in the progression of glioma. The role of brevican as a target for immunotherapy might be taken into consideration in future studies.

Conclusions

This study suggests that expression of brevican is associated with glioma cell adhesion, motility and tumor growth, and also is related to glioma cell differentiation, therefore it may be a marker for malignance degree of glioma

【 授权许可】

   
2012 Lu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Bolteus AJ, Berens ME, Pilkington GJ: Migration and invasion in brain neoplasms. Curr Neurol Neurosci Rep 2001, 1(3):225-232.
• [2]Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, et al.: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70(10):779-787.
• [3]Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB: Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009, 73(15):1200-1206.
• [4]Rauch U, Meyer H, Brakebusch C, Seidenbecher C, Gundelfinger ED, Beier DR, Fassler R: Sequence and chromosomal localization of the mouse brevican gene. Genomics 1997, 44(1):15-21.
• [5]Ruoslahti E: Brain extracellular matrix. Glycobiology 1996, 6(5):489-492.
• [6]Yamaguchi Y: Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci 2000, 57(2):276-289.
• [7]Gary SC, Zerillo CA, Chiang VL, Gaw JU, Gray G, Hockfield S: cDNA cloning, chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma. Gene 2000, 256(1–2):139-147.
• [8]Jaworski DM, Kelly GM, Piepmeier JM, Hockfield S: BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Res 1996, 56(10):2293-2298.
• [9]Zhang H, Kelly G, Zerillo C, Jaworski DM, Hockfield S: Expression of a cleaved brain-specific extracellular matrix protein mediates glioma cell invasion In vivo. J Neurosci 1998, 18(7):2370-2376.
• [10]Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT: Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res 2005, 65(15):6726-6733.
• [11]Lu R, Sun M, Feng J, Gao X, Guo L: Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer. BMC Cancer 2011, 11:270. BioMed Central Full Text
• [12]Choudhury KR, Yagle KJ, Swanson PE, Krohn KA, Rajendran JG: A Robust Automated Measure of Average Antibody Staining in Immunohistochemistry Images. J Histochem Cytochem 2010, 58(2):95-107.
• [13]LU RQ Wu HJ, Guo L: Construction, Expression of HE4 Fusion Protein and its identification. Chin J Lab Diag 2010, 14:17-19.
• [14]Nutt CL, Matthews RT, Hockfield S: Glial tumor invasion: a role for the upregulation and cleavage of BEHAB/brevican. Neuroscientist 2001, 7(2):113-122.
• [15]Hu B, Kong LL, Matthews RT, Viapiano MS: The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility. J Biol Chem 2008, 283(36):24848-24859.
• [16]Viapiano MS, Hockfield S, Matthews RT: BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion. J Neurooncol 2008, 88(3):261-272.
• [17]Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB, Moore PF, et al.: Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 2007, 85(2):133-148.
• [18]Goldbrunner RH, Bernstein JJ, Tonn JC: Cell-extracellular matrix interaction in glioma invasion. Acta Neurochir (Wien) 1999, 141(3):295-305. discussion 304–295
• [19]Jaworski DM, Kelly GM, Hockfield S: BEHAB, a new member of the proteoglycan tandem repeat family of hyaluronan-binding proteins that is restricted to the brain. J Cell Biol 1994, 125(2):495-509.
• [20]Seidenbecher CI, Richter K, Rauch U, Fassler R, Garner CC, Gundelfinger ED: Brevican, a chondroitin sulfate proteoglycan of rat brain, occurs as secreted and cell surface glycosylphosphatidylinositol-anchored isoforms. J Biol Chem 1995, 270(45):27206-27212.
• [21]Yamada H, Watanabe K, Shimonaka M, Yamaguchi Y: Molecular cloning of brevican, a novel brain proteoglycan of the aggrecan/versican family. J Biol Chem 1994, 269(13):10119-10126.
• [22]Viapiano MS, Matthews RT, Hockfield S: A novel membrane-associated glycovariant of BEHAB/brevican is up-regulated during rat brain development and in a rat model of invasive glioma. J Biol Chem 2003, 278(35):33239-33247.
• [23]Wang R, Clark RA, Mosher DF, Ren XD: Fibronectin’s central cell-binding domain supports focal adhesion formation and Rho signal transduction. J Biol Chem 2005, 280(31):28803-28810.
• [24]Yamaguchi Y: Brevican: a major proteoglycan in adult brain. Perspect Dev Neurobiol 1996, 3(4):307-317.
• [25]Lettau I, Hattermann K, Held-Feindt J, Brauer R, Sedlacek R, Mentlein R: Matrix metalloproteinase-19 is highly expressed in astroglial tumors and promotes invasion of glioma cells. J Neuropathol Exp Neurol 2010, 69(3):215-223.
• [26]Louis DN: Molecular pathology of malignant gliomas. Annu Rev Pathol 2006, 1:97-117.
• [27]Nutt CL, Zerillo CA, Kelly GM, Hockfield S: Brain enriched hyaluronan binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in Lewis rats. Cancer Res 2001, 61(19):7056-7059.
• [28]Stanton H, Melrose J, Little CB, Fosang AJ: Proteoglycan degradation by the ADAMTS family of proteinases. Biochim Biophys Acta 1812, 12:1616-1629.
• [29]Pilkington GJ: The paradox of neoplastic glial cell invasion of the brain and apparent metastatic failure. Anticancer Res 1997, 17(6B):4103-4105.
• [30]Subramanian A, Harris A, Piggott K, Shieff C, Bradford R: Metastasis to and from the central nervous system–the 'relatively protected site'. Lancet Oncol 2002, 3(8):498-507.
• [31]Cattaruzza S, Perris R: Proteoglycan control of cell movement during would healing and cancer spreading. Matrix Biol 2005, 24(6):400-417.